KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Other (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Receivables - Other data on record, last reported at $4.4 million in Q4 2025.

  • For Q4 2025, Receivables - Other fell 0.65% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $4.4 million, down 0.65%, while the annual FY2025 figure was $4.4 million, 0.65% down from the prior year.
  • Receivables - Other reached $4.4 million in Q4 2025 per AMRX's latest filing, down from $24.2 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $100.0 million in Q2 2022 and bottomed at $1.1 million in Q1 2021.
  • Average Receivables - Other over 5 years is $12.3 million, with a median of $3.4 million recorded in 2023.
  • Peak YoY movement for Receivables - Other: skyrocketed 3669.33% in 2021, then plummeted 96.64% in 2023.
  • A 5-year view of Receivables - Other shows it stood at $1.2 million in 2021, then soared by 54.45% to $1.8 million in 2022, then increased by 20.81% to $2.2 million in 2023, then soared by 103.0% to $4.5 million in 2024, then fell by 0.65% to $4.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $4.4 million in Q4 2025, $24.2 million in Q3 2025, and $3.7 million in Q2 2025.